Skip Navigation


Nucleic Acids Research Advance Access originally published online on December 13, 2007
Nucleic Acids Research 2008 36(1):e2; doi:10.1093/nar/gkm1094
This Article
Right arrow Full Text Freely available
Right arrow Print PDF (5838K) Freely available
Right arrow Screen PDF (656K) Freely available
Right arrowOA All Versions of this Article:
36/1/e2    most recent
gkm1094v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by de Martimprey, H.
Right arrow Articles by Malvy, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Martimprey, H.
Right arrow Articles by Malvy, C.
Related Collections
Right arrow Targeted inhibition of gene function
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 2008, Vol. 36, No. 1 e2
© 2007 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Methods Online

siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma

Henri de Martimprey1,2,*, Jean-Remi Bertrand1, Alfredo Fusco3, Massimo Santoro3, Patrick Couvreur2, Christine Vauthier2 and Claude Malvy1

1CNRS, UMR 8121, Univ Paris-Sud, Institut Gustave Roussy, 2CNRS, UMR 8612, Univ Paris-Sud, Faculté de Pharmacie and 3Istituto di Endocrinologia ed Oncologia Sperimentale del CNR "G.Salvatore", c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita’ Federico II, Naples, Italy

*To whom correspondence should be addressed. Tel: +33 142 115062; Fax: +33 142 115245; Email: martimprey{at}igr.fr

Received July 27, 2007. Revised October 17, 2007. Accepted November 23, 2007.

Delivery is a very important concern for therapeutic applications of siRNA. In this study, we have used chitosan-coated poly(isobutylcyanoacrylate) nanoparticles to deliver siRNA with a complementary sequence to the fusion oncogene ret/PTC1. By screening the mRNA junction we have selected a potent siRNA sequence able to inhibit this oncogene in a model of Papillary Thyroid Carcinoma cells. This siRNA sequence has then been validated by a shRNA approach using the same sequence. Furthermore, the high ret/PTC1 inhibition has triggered a phenotypic reversion of the transformed cells. We have designed well-defined chitosan decorated nanoparticles and succeeded to reduce their size. They have allowed to protect ret/PTC1 siRNA from in vivo degradation and leading to significant tumour growth inhibition after intratumoral administration.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.